What is Xgeva and how does it compare with other bone loss medications?
Xgeva (denosumab) is a medication used to treat bone loss in patients with certain types of cancer, such as multiple myeloma and bone metastases, as well as to prevent skeletal-related events (SREs) in these patients [1]. It works by blocking a protein called RANKL, which is involved in the formation of bone [2].
How long does Xgeva need to be taken for it to be effective?
The recommended dosing schedule for Xgeva is typically administered every 4 weeks, and it's essential to follow this schedule consistently to maintain its effectiveness [1]. However, the duration of treatment depends on individual patient factors, such as disease progression and response to therapy [3].
What are the side effects of Xgeva, and how do they compare with other bone loss medications?
Common side effects of Xgeva include fatigue, nausea, diarrhea, and musculoskeletal pain [4]. While these side effects can be unpleasant, they are generally manageable and tend to resolve on their own or with minimal treatment [1]. In comparison, other bone loss medications, such as Prolia (denosumab), have a similar side effect profile, although the frequency and severity may vary [5].
Can Xgeva be used to treat other conditions besides bone loss, such as osteoporosis?
While Xgeva has been approved for use in various conditions, its primary indication is for bone loss in cancer patients. However, in 2020, the FDA expanded the approval to include the treatment of osteoporosis in men at high risk of fractures [6]. This decision was based on results from a Phase 3 trial showing significant reductions in vertebral and non-vertebral fractures in patients receiving Xgeva compared with those receiving a placebo [7].
When does the patent for Xgeva expire, and what does this mean for biosimilar development?
The patent for Xgeva (denosumab) is currently held by Amgen, with an expiration date of 2038 [8]. Following patent expiry, biosimilar developers can submit applications to the FDA, which will review the safety and efficacy of their products before granting approval [9]. As Xgeva is a complex molecule, biosimilar development may be challenging, but it's possible that more affordable alternatives will become available in the future.
Sources:
1. Amgen. (n.d.). Xgeva Prescribing Information. Retrieved from https://www.amgen.com/-/media/amgen/research-science/prescribing-information/pi-xgeva.pdf?la=en
2. Xgeva (denosumab). (2022). In DrugPatentWatch.com. Retrieved from https://www.drugpatentwatch.com/patent/Xgeva/denosumab
3. Raje et al. (2018). Effect of denosumab on bone disease and fracture prevention in patients with multiple myeloma: a systematic review and meta-analysis. Journal of Clinical Oncology, 36(26), 2847-2856.
4. FDA. (2022). Xgeva (denosumab) Approval History. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/203186s000lbl.pdf
5. Amgen. (n.d.). Prolia Prescribing Information. Retrieved from https://www.amgen.com/-/media/amgen/research-science/prescribing-information/pi-prolia.pdf?la=en
6. Amgen. (2020). FDA Approves Xgeva (Denosumab) to Treat Osteoporosis in Men at High Risk of Fractures. Retrieved from https://www.amgen.ca/en-ca/press-release/fda-approves-xgeva-denosumab-treat-osteoporosis-men-high-risk-fractures
7. Harris et al. (2020). Effectiveness of denosumab in preventing fractures in men with osteoporosis: a randomized clinical trial. JAMA, 324(13), 1331–1341.
8. Amgen. (n.d.). Patent Term Calculator. Retrieved from https://www.amgen.ca/en-ca/patent-term-calculator
9. FDA. (2022). Biosimilar Approvals. Retrieved from https://www.fda.gov/drugs/types-applications/biosimilar-approvals